• Explore /
  • Poster
  • / A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).

A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).

Abstract Poster

Authors

null

Guilhem Roubaud

Department of Medical Oncology, Institut Bergonié, Bordeaux, France

Guilhem Roubaud , Carine A. Bellera , Sabrina Sellan-Albert , Mathilde Cabart , Diego Teyssonneau , Nam-Son Vuong , Ludivine Poignie , Nicolas Benziane-Ouaritini , Paul Sargos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05346848

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS349)

DOI

10.1200/JCO.2024.42.4_suppl.TPS349

Abstract #

TPS349

Poster Bd #

R1

Abstract Disclosures

Similar Posters

First Author: Martin T. King

First Author: Bertrand F. Tombal

Poster

2018 Genitourinary Cancers Symposium

Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer.

Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer.

First Author: Glenn Bubley

First Author: Andrew Leonard Laccetti